Answers are grounded in this paper and cite their sources.
Asthma is a heterogeneous illness. Despite a vast array of treatment options, a significant proportion of patients with asthma continues to lack control of their illness. We now have a new class of asthma therapy in our armamentarium: biologic agents. Presently, the current pricing for all of the biologic agents exceeds measures of cost-effectiveness. Optimal patient selection, through phenotypic indices, is the only likely way to allow these agents to be cost effective. This review examined the literature regarding biologic agents, which stressed attempts at optimizing choice.
No takes yet. Share an insight, caveat, or question.
John Oppenheimer (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: